Long-Term Neurological Safety in B-Cell ...
Type de document :
Article dans une revue scientifique: Article original
URL permanente :
Titre :
Long-Term Neurological Safety in B-Cell Lymphoma Patients Treated With Anti-CD19 CAR T-Cell Therapy
Auteur(s) :
Ursu, Renata [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Maillet, Didier [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Belin, Catherine [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Moroni, Christine [Auteur]
Psychologie : Interactions, Temps, Émotions, Cognition (PSITEC) - ULR 4072
Cuzzubbo, Stefania [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Vernier, Victoria [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Sirven-Villaros, Lila [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Carreau, Christophe [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Di Blasi, Roberta [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Thieblemont, Catherine [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Carpentier, Antoine F [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Hopital Saint-Louis [AP-HP] [AP-HP]
Maillet, Didier [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Belin, Catherine [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Moroni, Christine [Auteur]
Psychologie : Interactions, Temps, Émotions, Cognition (PSITEC) - ULR 4072
Cuzzubbo, Stefania [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Vernier, Victoria [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Sirven-Villaros, Lila [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Carreau, Christophe [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Di Blasi, Roberta [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Thieblemont, Catherine [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Carpentier, Antoine F [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Titre de la revue :
Neurology
Nom court de la revue :
Neurology
Pagination :
10.1212/WNL.0000000000201083
Éditeur :
Ovid Technologies (Wolters Kluwer Health)
Date de publication :
2022-07-18
ISSN :
1526-632X
Discipline(s) HAL :
Sciences cognitives
Résumé en anglais : [en]
Background and Objectives:Anti-CD19 CAR T-cell therapy is a promising treatment in relapsing B-cell lymphoma, but is frequently associated with acute neurotoxicity. Neurological long-term safety has not been thoroughly ...
Lire la suite >Background and Objectives:Anti-CD19 CAR T-cell therapy is a promising treatment in relapsing B-cell lymphoma, but is frequently associated with acute neurotoxicity. Neurological long-term safety has not been thoroughly assessed.Methods:All consecutive refractory lymphoma patients admitted in our center for CAR T-cell therapy underwent neurological examination, extensive neuropsychological assessment, brain MRI (except one patient) and completed self-administrated questionnaires at baseline. The patients who remained disease-free at 2 years were re-evaluated similarly. All neurological assessments were conducted by senior neurologists.Results:None of the 19 disease-free patients developed new neurological deficits or MRI changes when compared to baseline. There was no difference in cognitive performances before and two years after, even for the 11 patients who had developed acute neurotoxicity after CAR T-cells.In self-questionnaire assessments, cognitive complaint was stable, reported by 32% of patients at 2 years. We observed a reduction in HADS anxiety scores two years after treatment when compared to baseline (median score: 7/21 vs 4/21, p=0.01).Discussion:In conclusion, no significant neurocognitive or neurological disorders were observed in this cohort of patients, two years after treatment with anti-CD19 CAR T-cells.Lire moins >
Lire la suite >Background and Objectives:Anti-CD19 CAR T-cell therapy is a promising treatment in relapsing B-cell lymphoma, but is frequently associated with acute neurotoxicity. Neurological long-term safety has not been thoroughly assessed.Methods:All consecutive refractory lymphoma patients admitted in our center for CAR T-cell therapy underwent neurological examination, extensive neuropsychological assessment, brain MRI (except one patient) and completed self-administrated questionnaires at baseline. The patients who remained disease-free at 2 years were re-evaluated similarly. All neurological assessments were conducted by senior neurologists.Results:None of the 19 disease-free patients developed new neurological deficits or MRI changes when compared to baseline. There was no difference in cognitive performances before and two years after, even for the 11 patients who had developed acute neurotoxicity after CAR T-cells.In self-questionnaire assessments, cognitive complaint was stable, reported by 32% of patients at 2 years. We observed a reduction in HADS anxiety scores two years after treatment when compared to baseline (median score: 7/21 vs 4/21, p=0.01).Discussion:In conclusion, no significant neurocognitive or neurological disorders were observed in this cohort of patients, two years after treatment with anti-CD19 CAR T-cells.Lire moins >
Langue :
Anglais
Comité de lecture :
Oui
Audience :
Internationale
Établissement(s) :
Université de Lille
Équipe(s) de recherche :
Neuropsychologie & Audition
Date de dépôt :
2022-07-19T13:42:05Z
2022-08-24T06:52:08Z
2022-08-24T06:52:08Z
Fichiers
- WNL.0000000000201083.full.pdf
- Version finale acceptée pour publication (postprint)
- Accès libre
- Accéder au document